Cizzle Bio is moving its early cancer detection plans closer to a commercial setting, with founder and Chief Executive Officer Bill Behnke taking part in a national oncology commercialisation panel at the 25th Cancer Center Informatics Society Summit in San Diego.
Cizzle Bio is placing its blood test platform in front of the people and organisations involved in turning cancer research into usable clinical products. Diagnostic companies need more than strong laboratory results, they need a clear route into hospitals, clinics, physician networks, and payer systems.
Behnke joined a panel titled “Commercialization of Cancer Therapies: Bench to Bedside Drug Development Pipeline”. The discussion focused on how cancer innovations move from research into clinical practice, including the role of diagnostics, data, and partnerships. Cizzle Bio used the opportunity to underline its focus on early detection blood tests that can support doctors before cancers are usually found by symptoms or later-stage imaging.
The company’s most advanced lung cancer programme is based on CIZ1B, a blood-based biomarker linked to early-stage lung cancer. Cizzle Bio says the test has shown 95% sensitivity for Stage I lung cancer and a 96% negative predictive value.
Early-stage cancers may release very small amounts of DNA into the bloodstream, which can make detection harder. CIZ1B instead looks for a lung cancer-associated protein variant that the company says is more abundant, stable, and measurable in blood.
Cizzle Biotechnology Holdings plc (LON:CIZ) is a pioneering cancer diagnostics company, originally a spin-out from the University of York, and now listed on the London Stock Exchange.
